Stock CLEVELAND BIOLABS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Cleveland BioLabs, Inc. Nasdaq

Equities

US1858601032

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Cleveland BioLabs, Inc.
2021 Cleveland Biolabs : Cytocom Changing Name to Statera BioPharma MT
2021 Cleveland Biolabs, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Statera Biopharma Announces BF Borgers CPA PC as Independent Registered Public Accounting Firm
GL
Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-Q Filing
GL
Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products
GL
Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone
GL
Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod
GL
Statera Biopharma, Inc. Files Form 12b-25
GL
Statera Biopharma Announces Closing of $5.7 Million Underwritten Public Offering
GL
Statera Biopharma Announces Pricing of $5.7 Million Underwritten Public Offering
GL
CORRECTION -- Statera Biopharma Announces Proposed Underwritten Public Offering
GL
Statera Biopharma Announces Revised Preliminary Revenue and Financial Results of Fiscal Year 2021
GL
CORRECTION - Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19
GL
Statera Biopharma, Inc., Announces Central Institutional Review Board Approval of Phase 3 Clinical Trial for Pediatric Crohn’s Disease
GL
Statera Biopharma : to Participate in the Benzinga Healthcare Small Cap Conference
PR
Statera Biopharma : to Participate in the Cantor Virtual Global Healthcare Conference
PR
Cleveland Biolabs : OF RESTATED CERTIFICATE OF INCORPORATION (Form 8-K)
PU
Cleveland Biolabs : Cytocom Changing Name to Statera BioPharma
MT
CYTOCOM, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
Cleveland Biolabs : CYTOCOM, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
Cleveland Biolabs, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
Cleveland Biolabs : Cytocom Enters Research Collaboration Agreement With La Jolla Institute for Immunology
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. STAB Stock
  4. Stock
  5. News Cleveland BioLabs, Inc.